Disc Medicine, Inc. (IRON)

29.34 -0.70 (-2.33%) 收市：04:00PM EDT

Disc Medicine, Inc.

321 Arsenal Street
Suite 101
Watertown, MA 02472
United States
617 674 9274
https://www.discmedicine.com

版塊: Healthcare
行業: Biotechnology
全職員工: 74

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Brian MacDonald ChB, MB, Ph.D.	Founder & Chair of Scientific Advisory Board	88.54k	無	1960
Ms. Jean M. Franchi	Chief Financial Officer	無	無	1966
Mr. Jonathan Yu M.B.A.	Chief Opearating Officer	539.32k	無	1981
Dr. Rahul Khara J.D., Pharm.D.	General Counsel, Compliance Officer & Secretary	無	無	1982
Mr. Srikanth Venkatraman Ph.D.	Senior VP & Head of Chemistry	無	無	無
Ms. Hua Yang Ph.D.	Senior Vice President of Nonclinical Development	無	無	無
Ms. Pamela Stephenson M.P.H.	Chief Commercial Officer	無	無	1968
Ms. Sonia Razzetti Ph.D.	Senior VP of Quality	無	無	無

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

公司管治

截至 2024年5月1日 止，Disc Medicine, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：4；股東權利：4；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。